Colon Pharmaceutical announced that its holding subsidiary, Sichuan Colun Botai Biomedical Co., Ltd., has received a clinical trial notice from the Drug Evaluation Center of the State Drug Administration approving the clinical trial application of the novel dual-load ADC drug SKB565 for the treatment of advanced solid tumors. This is the first clinically-advanced dual-load antibody conjugate drug from Colombotte.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.